News | August 01, 2023
Concord Biotech’s IPO to open on 4th August, 2023
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
Application being reviewed under the FDA Project Orbis framework, which enables concurrent reviews among US, Australia, Canada, Switzerland, Singapore and United Kingdom health authorities
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis,
The funding will be used to expand the product line for remote patient monitoring and to scale the business across Asia and Africa
With a focus on optimizing patient experience with next-generation oral dosage forms, the US facility complements the cutting-edge research activities of Roquette’s existing pharma innovation centers in France and Singapore
Clinical Decision Support Systems' huge potential to help ensure that each patient can receive high-quality care; study shows a reduction in diagnostic errors from 24% to 2%
Abbas will closely partner with CBC's business teams to identify, assess, and pursue investment opportunities and strategic acquisitions
The award recognizes and supports promising female scientists working in mass spectrometry
Agasta Software is engaged in research, development and commercialization of medical devices
Subscribe To Our Newsletter & Stay Updated
